Emory is full of fledgling biomedical proto-companies. Some of them are actual corporations with employees, while others are ideas that need a push to get them to that point. Along with the companies highlighted by the Emory Biotech Consulting Club, Dean Sukhatme’s recent announcement of five I3 Venture research awards gives more examples of early stage research projects with commercial potential.

This is the third round of the I3 awards; the first two were Wow! (basic discovery) and Synergy II/Nexus (promoting interdisciplinary collaboration). For the five Venture awards, the Dean’s office is providing a total of $100,000. The companies will then use the momentum to seek larger amounts of funding from various sources. Lab Land is still collecting information on the projects:

Faculty	Name	Technology	Relevant links
Ray Dingledine + Thota Ganesh	Pyrefin	EP2 receptor antagonists vs epilepsy, pain, inflammation	New class of potential drugs inhibits inflammation in brain
Mark Goodman, W. Robert Taylor	Microbial Medical	PET imaging agent for detection of bacterial infections	Spoonful of sugar helps infection detection
Carlos Moreno + Christian Larsen	ResonanceDx	Miniaturized rapid creatinine test for point of care use
Edmund Waller + Taofeek Owonikoko	Cambium Oncology	Enhancing responsiveness of pancreatic cancer to immunotherapy	The Company’s lead compound was effective in animal studies for pancreatic cancer, melanoma, leukemia and lymphoma.
Chunhui Xu	TK	High-throughput screening for antiarrhythmic drugs using cardiomyocytes	Fetal alcohol toxicity – in a dish // Cardiac ‘disease in a dish’ models advance arrhythmia research